HENDERSON, Nev., Sept. 13, 2023 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, is hosting a Key Opinion Leader (“KOL”) roundtable discussion in Athens this weekend, bringing together world-renowned experts in sepsis.
Chaired by Professor Djillali Annane, Professor of Medicine at University Paris Saclay-UVSQ , and one of the world’s leading specialists in sepsis, the session will include the challenges of sepsis, the connection between Neutrophil Extracellular Traps (“NETs”) and sepsis and how Volition’s Nu.Q® NETs technology could potentially be used effectively in clinical practice.
Volition’s event is being hosted by Professor Evangelos J. Giamarellos-Bourboulis, Professor of Internal Medicine at The National and Kapodistrian University of Athens in Greece and Chairman of the European Sepsis Alliance.
Professor Djillali Annane said: “We are delighted to bring together some of the world’s most distinguished experts in the field of sepsis, spanning a wide range of specialisms including intensive care medicine, paediatric sepsis, immunology, ctDNA, haematology, and critical care medicine.
“Together, we will discuss the challenges we face in detecting and treating sepsis, and the role of NETs. We will share research around potential treatments, examine different approaches to personalizing care, and consider how best to introduce pioneering diagnostic tools, like Volition’s Nu.Q® NETs test, into clinical practice.”
Dr. Andrew Retter, Medical Consultant at Volition and a leading UK-based Intensive Care Consultant added: “Nu.Q® NETs, Volition’s nucleosome quantification technology, is a simple, low cost and routine blood test which can detect clinically elevated levels of NETs by identifying the unique biomarker H3.1. Composed of decondensed chromatin, NETs play an important role in our immune system with a unique ability to counter infections by trapping and killing bacterial and viral particles. However, abnormal levels have been linked to a range of life-threatening conditions including severe sepsis, where they can provide valuable prognostic information.
“Volition is committed to collaborating closely with KOLs and centers of excellence worldwide, to ensure that the Nu.Q® NETs test can be introduced effectively into clinical settings, to advance patient care and improve outcomes. We look forward to sharing the outputs from this invaluable KOL roundtable.”
Volition’s Nu.Q® NETs test is CE-marked, enabling clinical use across Europe. Volition continues to liaise with the United States Food and Drug Administration regarding its U.S. clinical and regulatory program.
Sepsis is the number one cause of death in hospitals worldwide and accounts for at least 11 million deaths per year. Volition’s event takes place during Sepsis Awareness Month and coincides with World Sepsis Day, a global initiative to raise awareness around the disease.
Notes
- Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multi-organ failure, and death – especially if not recognized early and treated promptly. (Global Sepsis Alliance – World Sepsis Day website)
- A recent study estimated that in 2017 there were 48.9 million cases and 11 million sepsis-related deaths worldwide, which accounted for almost 20% of all global deaths. (World Health Organisation).
- In 2017, almost half of all global sepsis cases occurred among children, with an estimated 20 million cases and 2.9 million global deaths in children under 5 years of age. (World Health Organisation).
About Volition
Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
For more information about Volition’s Nu.Q® technology go to: www.volition.com
The contents found at the Volition, the World Sepsis Day and the World Health Organisation website addresses are not incorporated by reference into this document and should not be considered part of this document. The website addresses are included in this document as inactive textual references only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition’s expectations related to the timing and launch of product sales, and the potential uses, benefits and effectiveness of its Nucleosomics™ technology platform, including the Nu.Q® NETs test. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests, a failure by the marketplace to accept Volition’s, Nu.Q® NETs test or other products based on its Nucleosomics™ platform; Volition’s failure to secure adequate intellectual property protection; Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volition-hosts-key-opinion-leader-roundtable-on-sepsis-management-301925995.html
SOURCE VolitionRx Limited
